Patients who respond to ADCETRIS have the potential to respond again1
Data were collected from 21 R/R HL patients retreated with ADCETRIS*1
- Median PFS = 9.9 months
- Median OS = not reached
-
Median DOR
- OR patients = 9.2 months
- CR patients = 9.4 months
-
45% of CR patients (including HL / sALCL) achieved median duration of response of >1 year
- 2 subsequently received allogeneic stem cell transplant
Objective response rate*
* Included patients who previously achieved a CR or PR with ADCETRIS
**1 patient had no post-baseline response assessment
Adapted from Bartlett et al, 2014.
Reuse with ADCETRIS provides tumour reduction in 79% of HL patients1
Maximum reduction in target lesion size
*Tumour reduction measurement available for 19 patients
Adapted from Bartlett et al. 2014
ADCETRIS has a generally manageable toxicity profile1,2
Treatment-emergent adverse events occurring in ≥20% of R/R HL patients (n=21) in this study3
| n (%) | |
|---|---|
| Any event2 | 20 (95) |
| Peripheral sensory neuropathy | 12 (57) |
| Nausea | 9 (43) |
| Diarrhoea | 9 (43) |
| Fatigue | 11 (52) |
| Headache | 6 (29) |
| Peripheral motor neuropathy | 6 (29) |
| Arthralgia | 7 (33) |
| Dyspnoea | 7 (33) |
| Pyrexia | 7 (33) |
| Anaemia | 6 (29) |
| Back pain | 5 (24) |
| Cough | 5 (24) |
| Dizziness | 5 (24) |
With the exception of higher incidence of peripheral motor neuropathy (29% total versus 11%) the rates of AEs were consistent with those observed in the pivotal phase 2 trial in R/R HL1,3
Reuse
Please use the following link to access the CDF criteria for reuse
Please refer to the guidance in your local NHS service for further information on funding.
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies1
Bartlett NL, et al. J Haem Onc. 2014; 7 (24): 1-8
- Median number of prior chemotherapy regimens was 4 (range 2–12)
- Median time between last ADCETRIS dose on prior study and first dose of retreatment was 11.4 months (range 4–45)
- 24% of HL patients were refractory to their most recent prior therapy
- The median number of cycles of ADCETRIS retreatment across all HL and sALCL patients was 7 (range 2 to 37 cycles)†
†ADCETRIS is licenced up to a maximum of 16 cycles2
Study details
References
- Bartlett NL, et al. J Haem Onc. 2014; 7 (24): 1-8
- ADCETRIS Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2859/smpc
- Takeda UK Ltd. - Data on File - UK/DF/1605/0010
and ADCETRIS are registered trademarks of Takeda Pharmaceutical Company Limited.
